A Cancer Research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  2004-01-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00280-003-0733-6PMID 14722733
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth

  2004cited by this paper
• Measurement of steroid hormone receptors in breast cancer patients on tamoxifen

  2004cited by this paper
• Idoxifene versus tamoxifen: a randomized comparison in postmenopausal patients with metastatic breast cancer.

  2003cited by this paper
• Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.

  2002cited by this paper
• Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice.

  2000cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998cited by this paper
• Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998cited by this paper
• Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.

  1998cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials

  1998cited by this paper
• The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance.

  1997cited by this paper
• Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

  1996cited by this paper
• Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer.

  1995cited by this paper
• Idoxifene: report of a phase I study in patients with metastatic breast cancer.

  1995cited by this paper
• Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer.

  1995cited by this paper
• 4′-Substituted analogues of idoxifene: Antiestrogens and calmodulin antagonists

  1995cited by this paper
• Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer.

  1994cited by this paper
• Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration.

  1993cited by this paper
• Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites.

  1993cited by this paper
• Effect of oestrogen receptor status and time on the intra-tumoural accumulation of tamoxifen and N-desmethyltamoxifen following short-term therapy in human primary breast cancer

  1993cited by this paper
• Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients.

  1992cited by this paper
• Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors.

  1992cited by this paper
• Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer.

  1991cited by this paper
• Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen.

  1991cited by this paper
• Tamoxifen as an Agonist for Metastatic Breast Cancer

  1990cited by this paper
• Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer.

  1990cited by this paper
• Metabolism of the 4-iodo derivative of tamoxifen by isolated rat hepatocytes. Demonstration that the iodine atom reduces metabolic conversion and identification of four metabolites.

  1990cited by this paper
• Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer.

  1990cited by this paper
• The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast.

  1988cited by this paper
• Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration.

  1988cited by this paper
• The value of high dose tamoxifen in postmenopausal breast cancer patients progressing on standard doses: a pilot study.

  1988cited by this paper
• Long-term adjuvant therapy with tamoxifen: effects on sex hormone binding globulin and antithrombin III.

  1987cited by this paper
• Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route.

  1987cited by this paper
• A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd.

  1984cited by this paper
• Trial of tamoxifen at a dose of 40 mg daily after disease progression during tamoxifen therapy at a dose of 20 mg daily.

  1982cited by this paper
• An evaluation of tamoxifen dose escalation in advanced breast cancer.

  1982cited by this paper
• Serum concentrations of tamoxifen and major metabolite during long-term nolvadex therapy, correlated with clinical response.

  1980cited by this paper
• Serum concentrations of tamoxifen and major metabolite during long-term nolvadex therapy, correlated with clinical response.

  1980cited by this paper
• The effect of tamoxifen and stilboestrol on plasma hormone levels in postmenopausal women with advanced breast cancer.

  1979cited by this paper
• Hormone receptors: their role in predicting prognosis and response to endocrine therapy.

  1978cited by this paper
• Assessment of response to therapy in advanced breast cancer.

  1977cited by this paper

• Phenoxyalkyl cyclic and acyclic amine derivatives: what do they teach us about scaffold-based drug design?

  2024cites this paper
• Effectiveness of Selective Estrogen Receptor Modulators in Breast Cancer Therapy: An Update.

  2022cites this paper
• In vitro and in vivo antiestrogenic effects of dichloromethane-methanol extract of Crateva adansonii DC.

  2018cites this paper
• Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment.

  2017cites this paper
• Crateva adansonii DC, an African ethnomedicinal plant, exerts cytotoxicity in vitro and prevents experimental mammary tumorigenesis in vivo.

  2016cites this paper
• An overview of current and emerging SERMs.

  2014cites this paper
• Drug Response Heterogeneity and the Genetic Variability of Cytochrome P450–Metabolizing Enzymes

  2014cites this paper
• Selective estrogen receptor modulators: tissue specificity and clinical utility

  2014cites this paper
• Selective estrogen receptor modulators: tissue specificity and clinical utility

  2014cites this paper
• Development of new estrogen receptor-targeting therapeutic agents for tamoxifen-resistant breast cancer.

  2013cites this paper
• Use of preclinical and early clinical data for dose selection of a selective estrogen receptor modulator toremifene in treatment of breast cancer

  2012cites this paper
• Estrogen Receptor Modulators and Down Regulators

  2012cites this paper
• Emerging Selective Estrogen Receptor Modulators

  2012cites this paper
• Pharmacology and clinical applications of selective estrogen receptor modulators

  2009cites this paper
• Polymorphism of human cytochrome P450 enzymes and its clinical impact

  2009cites this paper
• Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development.

  2009cites this paper
• Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development.

  2009cites this paper
• Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development.

  2009cites this paper
• Selective Estrogen Receptor Modulators: An Update on Recent Clinical Findings

  2008cites this paper
• The future of the new selective estrogen receptor modulators

  2007cites this paper
• Estrogen receptor modulators and down regulators: optimal use in postmenopausal women with breast cancer.

  2007cites this paper
• Sex hormones and related compounds, including hormonal contraceptives

  2007cites this paper
• Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women.

  2006cites this paper
• Treatment of Postmenopausal Breast Cancer with Selective Estrogen Receptor Modulators (SERMs)

  2006cites this paper
• Endocrinology and hormone therapy in breast cancer: Selective oestrogen receptor modulators and downregulators for breast cancer – have they lost their way?

  2005cites this paper
• Selective oestrogen receptor modulators and downregulators for breast cancer - have they lost their way?

  2005cites this paper
• Selective estrogen receptor modulators

  2005cites this paper
• Maintaining the cold chain shipping environment for Phase I clinical trial distribution.

  2005cites this paper